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KEYWORDS fibromuscular dysplasia, renal arteries, balloon angioplasty F ibromuscular dysplasia (FMD) is a nonatherosclerotic and noninflammatory disease that most commonly affects the renal and carotid arteries but can involve any artery. 1 The prevalence of FMD is approximately 0.5% to 5% of the population, and the disease has been gaining popularity in the recent press because of its potential underdiagnosis. 2 FMD occurs predominantly in middle-aged Caucasian women, and its pathogenesis is not fully understood. Genetic ties have been discovered between first-degree relatives, with the disease transmitted as autosomal dominant with incomplete penetrance and variable expression. Many cases have no family history, and risk factors, such as smoking and oral contraceptives, have also been associated. Even mechanical stress in the setting of renal ptosis has been theorized as a potential etiology. 3 Histopathological classification of renal artery FMD as originally proposed by McCormack and coworkers is based on the predominant arterial wall layer involved. 4 The three most common and classically described subtypes include medial (70% of cases), perimedial (15-25%), and intimal fibrodysplasias (1-2%). 5 Both the medial and perimedial fibrodysplasias form alternating stenoses and aneurysms such that their angiographic appearance is that of a "string of beads," frequently involving the bilateral renal arteries. Medial fibrodysplasia tends to create aneurysms larger than the expected luminal diameter of the artery from which they originate and rarely leads to occlusion (Fig. 1) . Perimedial fibrodysplasia creates aneurysms smaller than the expected luminal diameter, resulting in highly stenotic lesions than can progress to occlusion (Fig. 2) . Intimal fibrodysplasia creates smooth narrowings that can be focal or tubular, typically occurs in children, and can progress to occlusions. 6 Less common subtypes continue to be described, and any of the subtypes can coexist within a single patient (Fig. 3) .
Percutaneous transluminal renal angioplasty (PTRA) has been the mainstay of treatment for renal FMD, with technical success rates approaching 100% and excellent reported rates of improved or even cured hypertension. 7 According to recent American College of Cardiology guidelines, the indications for intervention include resistant hypertension, intolerance to hypertensive medications, noncompliance with medications, and renal impairment or cortical loss from ischemia. 8 This article focuses on modern technical considerations in the treatment of renal FMD.
Patients presenting for treatment of FMD are typically younger, and therefore common femoral artery access is not usually complicated by calcific atherosclerotic changes. A diagnostic aortogram is part of the initial diagnostic workup, but alone does not provide adequate evaluation of the renal arteries. Selective renal angiograms are essential, and often multiple views are required to fully profile the renal arteries and define the branch and intrarenal arterial anatomy. Digital subtraction angiography is the gold standard in diagnosis of FMD. Although the disease is detectable on ultrasound and magnetic resonance imaging, multidetector computed tomography angiography holds the greatest accuracy in the noninvasive diagnosis of FMD, with sensitivity and specificity reported to be 64-99% and 89-98%, respectively (Fig. 4) . 9 The diagnostic evaluation and interventional treatment of renal FMD can nearly always be accomplished via the common femoral artery. A diagnostic aortogram using a flush catheter and selective renal arteriograms using a reverse curve or downward-directed selective catheter (Sos II, Cobra 2, AngioDynamics, Glen Falls, NY; Simmonds I, Cook, Inc, Bloomington, IN; RC 2, Boston Scientific, Natick, MA; RIM, Cordis Endovascular, Warrenton, NJ) are performed. FMD typically involves the distal main renal artery and its branches, so at least two oblique selective angiograms should be obtained of each renal artery to define the lesions and their relationship to branch vessels. Anatomic variations are common, and careful evaluation of preprocedural cross-sectional imaging is helpful in calculating the optimal fluoroscopic projections. In addition, FMD is bilateral in more than 33% of patients, so meticulous evaluation of both kidneys and their intrarenal branches is requisite. On rare occasions a brachial artery approach is preferable when renal arteries originate from the aorta in a very caudal orientation.
Stenotic lesions should be crossed carefully using a softtipped wire, such as a 0.035-inch Bentson (Cook, AngioDynamics), after the selective catheter has engaged the renal artery ostium. Once the lesion is crossed by the catheter, the wire can be exchanged for a stiffer wire, such as a Wholey or TAD II (Malinkrodt, St Louis, MO). A J-tipped guidewire, such as a Rosen (Cook, AngioDynamics), can be used if the most distal renal artery and its branches are uninvolved and a catheter has been advanced distal to the diseased segment to allow exchange for the stiffer Jtipped guidewire. Use of a stiffer guidewire allows for advancement of the guiding sheath over its dilator into the proximal trunk of the renal artery. Five-or 6-Fr precurved renal-shaped guiding sheaths ( Fig. 5 ; Cook, Boston Scientific, Cordis Endovascular) allow for better stability of the dilation system. Injecting the side port of the guiding sheath allows for rapid angiographic assessment following balloon dilatation. The guiding sheath also facilitates balloon catheter exchanges.
Many types of balloon catheter systems are available for treatment. Five-French balloon dilation systems used over 0.035-inch guidewires have the advantage of being able to Fig. 5 ; Medtronic, Minneapolis, MN; Cook; Boston Scientific; Cordis Endovascular) and are lower profile, more flexible, and track better than the larger systems; all of which are features that decrease the potential for inducing vasospasm. These smaller balloon dilation systems also have the advantage of being easier to use in very angulated renal arteries, tight stenoses, small branch vessels, and pediatric patients. Smaller balloon catheter systems also enable the use of two kissing balloons via one guiding system. A three-way sidearm adapter (Microvena Corporation, White Bear Lake, MN) allows use of two guidewires and two balloon catheters via one guide catheter (typically 7-8 Fr), while minimizing blood loss and eliminating the need for bilateral femoral artery access (Figs. 3 and 6) .
Balloon diameter size is selected to be 10-20% greater than the expected normal artery luminal diameter, which can be dif- ficult to estimate in the setting of extensive disease or poststenotic dilatation. As a general rule, it is best to underestimate balloon size and redilate with a larger balloon if needed. The goal of PTRA in the setting of FMD is to disrupt the web-like stenoses. The treatment of renal FMD poses some challenges in comparison with the treatment of atherosclerotic renal artery disease, particularly when lesions involve the distal main renal artery, branchpoints, or small branch vessels (Fig. 7) . Oftentimes following PTRA, the nature of the disease leaves a patent but unesthetic result. Aggressive and unnecessary repeat angioplasty for a better esthetic result can lead to severe dissections or even ruptures. Therefore, it is critical to monitor the patient's symptoms during balloon inflations to gauge whether the balloon size is appropriate or can be increased.
Cutting balloons have been shown to be efficacious in the setting of stenotic lesions of FMD that are resistant to conventional balloon angioplasty, particularly in stenoses related to intimal fibrodysplasia. Cutting balloons offer longitudinal blades that "cut" the vessel wall, reduce elastic recoil, and can improve the technical result and possibly long-term pat- ency. 10, 11 Typically cutting balloons are undersized to the target vessel diameter by 1 mm to account for the blades and to decrease the risk of vessel rupture, which is a known complication. 12 Prolonged inflation is not required with cutting balloons given the intended purpose, but the deflated cutting balloon can be rotated and reinflated to provide additional effect.
Stenting is reserved exclusively for treating a complication of PTRA, such as a dissection or rupture that cannot otherwise be fixed with a balloon. Surgical bypass is considered primarily in the setting of macroaneurysms in which covered stents cannot be employed, resistant intimal fibroplastic lesions, or in complex lesions in which endovascular therapy cannot be used or has failed.
During the PTRA procedure, intravenous heparin is administered to keep the activated clotting time (ACT) above 220 seconds. Typically 50-70 IU/kg body weight of unfractionated heparin is administered intravenously and an ACT is checked. Supplemental redosing of heparin is performed at hourly intervals as necessary. Bivalirudin (Angiomax; The Medicines Company, Parsippany, NJ) has been incorporated into some practices.
Renal artery spasm is frequently encountered during PTRA for FMD. Intra-arterial injection of pharmacologic agents directly into the renal artery is useful in the prevention or alleviation of vasospasm. Nitroglycerin (American Regent, Shirley, NY) acts as a smooth vasodilator and can be injected in 100-and 200-g increments. The effective half-life of nitroglycerin is in the order of seconds to minutes, and redosing can be performed frequently if the patient's blood pressure permits. Calcium channel blockers, such as verapamil (Hospira, Lake Forest, IL), can also be used to prevent or alleviate vasospasm by direct injection into the renal artery. Verapamil is administered in 2.5-mg increments and has an effective half-life of minutes to hours. Verapamil can induce bradycardia or complete heart block, particularly if the patient is already taking a beta-blocker or has an underlying conduction abnormality. Therefore, knowledge of the patient's medications and electrocardiogram before the procedure is necessary. In addition, caution must be taken when using multiple agents to avoid severe hypotension. Should severe hypotension occur, intravenous hydration is considered the first line of treatment. 13 Documentation of baseline preprocedural blood pressures is essential in determining treatment effect. The patient's antihypertensive medications are not typically held the morning of the procedure. The patient's blood pressure is monitored closely both during and following PTRA. At our institution, following the procedure, patients are observed in the interventional radiology recovery area for 2-4 hours while they are hydrated with normal saline (a minimum of 125 mL/h and more as necessary) and closely monitored. On occasion, it becomes necessary to administer a bolus of 500 mL of normal saline to compensate for the peripheral vasodilation that occurs following an effective PTRA. The patients are then observed overnight and further hydration is given as necessary.
Patients are discharged the next day and are told to take 81-325 mg/d of acetylsalicylic acid daily for at least 6 months. The patient is seen in follow-up in our clinic in 4-6 weeks. Antihypertensive medications are withheld as necessary, recognizing that sympatholytic agents and beta-blockers should be gradually tapered to reduce the risk of rebound hypertension or tachycardia. Patients are also asked to see their primary care physician within 1 week for a blood pressure check, recognizing that it may take several months to establish a new baseline on their antihypertension medical regimen.
Patency rates following PTRA for FMD have been reported to be as high as 87% over 10 years. 14 Follow-up angiograms are warranted if hypertension recurs, with restenosis manifesting in previously treated areas or new stenoses appearing in either renal artery. Follow-up angiograms have also provided insight into vessel remodeling after treatment. In our experience, treated arteries can heal with patent lumens that become more narrow than the expected normal caliber of the vessel (Fig. 1C) .
Renal artery FMD is a treatable cause of hypertension. 16 The distribution of the disease typically involves the mid and distal renal arteries and branchpoints and poses treatment challenges that separate FMD from atherosclerotic disease. 17 The development of smaller balloon dilation systems offers safe and highly effective treatment options for technically difficult lesions. Newer technology, such as cutting balloons, add to the armamentarium for treatment of resistant lesions, particularly in the setting of intimal fibrodysplasia. However, we must be mindful of complications, such as ruptures that can occur with over aggressive application of cutting or noncompliant balloons. Overall, the endovascular treatment of FMD is an effective technique with high rates of improved or cured hypertension.
